Oncolys Biopharma Inc
TSE:4588
Intrinsic Value
Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatmen... [ Read More ]
The intrinsic value of one Oncolys Biopharma Inc stock under the Base Case scenario is 51.6 JPY. Compared to the current market price of 668 JPY, Oncolys Biopharma Inc is Overvalued by 92%.
Valuation Backtest
Oncolys Biopharma Inc
Run backtest to discover the historical profit from buying and selling Oncolys Biopharma Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Oncolys Biopharma Inc
| Current Assets | 2B |
| Cash & Short-Term Investments | 1.5B |
| Receivables | 101.7m |
| Other Current Assets | 321.3m |
| Non-Current Assets | 84.7m |
| Long-Term Investments | 21m |
| Other Non-Current Assets | 63.7m |
| Current Liabilities | 378.5m |
| Accrued Liabilities | 19.1m |
| Other Current Liabilities | 359.4m |
| Non-Current Liabilities | 188m |
| Long-Term Debt | 179.8m |
| Other Non-Current Liabilities | 8.1m |
Earnings Waterfall
Oncolys Biopharma Inc
|
Revenue
|
63m
JPY
|
|
Cost of Revenue
|
-32.4m
JPY
|
|
Gross Profit
|
30.6m
JPY
|
|
Operating Expenses
|
-2B
JPY
|
|
Operating Income
|
-1.9B
JPY
|
|
Other Expenses
|
-8.5m
JPY
|
|
Net Income
|
-1.9B
JPY
|
Free Cash Flow Analysis
Oncolys Biopharma Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Oncolys Biopharma Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Oncolys Biopharma Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Oncolys Biopharma Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Oncolys Biopharma Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Oncolys Biopharma Inc
Shareholder Return
Price
Oncolys Biopharma Inc
| Average Annual Return | -29.16% |
| Standard Deviation of Annual Returns | 27.65% |
| Max Drawdown | -87% |
| Market Capitalization | 13.7B JPY |
| Shares Outstanding | 20 290 462 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 33 full-time employees. The company went IPO on 2013-12-06. The firm operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The firm's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one Oncolys Biopharma Inc stock under the Base Case scenario is 51.6 JPY.
Compared to the current market price of 668 JPY, Oncolys Biopharma Inc is Overvalued by 92%.
You don't have any saved screeners yet
